de Jong Tamarah D, Vosslamber Saskia, Verweij Cornelis L
Arthritis Res Ther. 2014;16(3):110. doi: 10.1186/ar4565.
To develop personalized medicine strategies for improvement of patient management in rheumatoid arthritis, the clinical and molecular properties of the individual patients need to be well characterized. A crucial step in this approach is to discover subgroups of patients that are characterized by a good or poor treatment outcome. Dennis and colleagues have identified distinct pretreatment gene expression profiles in affected synovial tissue specimens and a tissue type-related systemic protein pattern which are associated with a positive or negative clinical outcome to monotherapy with adalumimab (anti-TNFα) and tocilizumab (anti-IL-6 receptor). These observations assign biological pathways associated with response outcome and provide evidence for the existence of systemic,easy-to-measure predictive biomarkers for clinical benefit of these biologics.
为制定改善类风湿关节炎患者管理的个性化医疗策略，需要充分了解个体患者的临床和分子特征。该方法的关键一步是发现治疗结果良好或不佳的患者亚组。丹尼斯及其同事在受影响的滑膜组织标本中确定了不同的治疗前基因表达谱以及与组织类型相关的全身蛋白模式，这些与使用阿达木单抗（抗TNFα）和托珠单抗（抗IL-6受体）单药治疗的阳性或阴性临床结果相关。这些观察结果确定了与反应结果相关的生物学途径，并为这些生物制剂临床获益的全身性、易于测量的预测生物标志物的存在提供了证据。
